Caring Cross Announces Dosing of First Participant in Anti-HIV DuoCAR-T Cell Therapy Phase 1/2a Clinical Trial

Published on :

Caring Cross, a 501(c)(3) non-profit dedicated to accelerating the development of advanced medicines and enabling access to cures for all patients, everywhere, announced the dosing of the first participant in a Phase 1/2a clinical trial evaluating the organization’s Anti-HIV DuoCAR-T cell therapy. Caring Cross has designed its Anti-HIV DuoCAR-T cell therapy to potentially eliminate HIV-infected cells and suppresses HIV infection long-term in the body after a single infusion.

Caring Cross Presents Research Involving Anti-HIV DuoCAR-T Cell Therapy at the Conference on Retroviruses and Opportunistic Infections (CROI) 2022

Published on :

Caring Cross, a 501(c)(3) non-profit dedicated to accelerating the development of advanced medicines and enabling access to cures for all patients, everywhere, announced that Kim Anthony-Gonda, Ph.D., Director of Infectious Diseases at Caring Cross, presented a poster highlighting the organization’s Anti-HIV DuoCAR-T Cell Therapy at the Conference on Retroviruses and Opportunistic Infections (CROI) 2022.